department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Jevtana · pharmadog

pharmadog
drugs
Jevtana

drug

patient view →

cabazitaxel

Marketedupdated 2mo ago

by Sanofi-Aventis US LLC

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Jevtana

generic

cabazitaxel

indication

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 49m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Oct 27, 2030

~4.3 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (10)

Apr 27, 2031patentUS 10583110*PED4.8y
Apr 27, 2031patentUS 10716777*PED4.8y
Apr 27, 2031patentUS 12453712*PED4.8y
Apr 27, 2031patentUS 8927592*PED4.8y
Oct 27, 2030method-of-use (U-2753)US 105831104.3y
Oct 27, 2030method-of-use (U-2856)US 107167774.3y
Oct 27, 2030method-of-use (U-4334)US 124537124.3y
Oct 27, 2030method-of-use (U-3200)US 89275924.3y
Jun 10, 2026patentUS 7241907*PED
Dec 10, 2025compositionUS 7241907

Trials studying cabazitaxel

phase3A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancerrecruitingn=750
phase2Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPCcompletedn=96
phase2Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Canceractive not recruitingn=120
phase2Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)recruitingn=220
phase1A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancerrecruitingn=300
phase2A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumorscompletedn=34
phase2A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Canceractive not recruitingn=41
phase3Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancercompletedn=195

more trials →